SCHEMBL6610667

SCHEMBL6610667

CC(C)(O)c1ccc(CN)c(F)c1.O=C(O)c1cncnc1Oc1ccc2c(c1)OCO2

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
PDE4C Q08493 1/20 0.43
PDE4D Q08499 1/20 0.43
MAPK8 P45983 1/20 0.35
MAPK10 P53779 1/20 0.35
LMNA P02545 3/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
TSHR P16473 2/20 0.35
PTGER4 P35408 1/20 0.35
RAB9A P51151 5/20 0.34
NPC1 O15118 4/20 0.34
PKM P14618 1/20 0.34
NOS2 P35228 2/20 0.33
KMT2A Q03164 3/20 0.32
MEN1 O00255 1/20 0.32
TP53 P04637 1/20 0.32
GAA P10253 1/20 0.32
MAPK1 P28482 3/20 0.32
ALDH1A1 P00352 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6610662 0.85 PDE4A (0.56) PDE4APDE4BPDE4CPDE4DRAB9A
SCHEMBL6611896 0.81 LMNA (0.45) PDE4APDE4BPDE4CPDE4DMAPK8
SCHEMBL6615489 0.76 KMT2A (0.47) PDE4APDE4BPDE4CPDE4DSMN1; SMN2
SCHEMBL7367201 0.74 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DMAPK8
SCHEMBL6613947 0.73 ALDH1A1 (0.45) PDE4APDE4BPDE4CPDE4DMAPK8
SCHEMBL6486741 0.73 PDE4A (0.51) PDE4APDE4BPDE4CPDE4DRAB9A
SCHEMBL6612468 0.72 TSHR (0.50) LMNASMN1; SMN2TSHRRAB9ANPC1
SCHEMBL6614342 0.70 ALDH1A1 (0.45) SMN1; SMN2NPC1KMT2AMEN1ALDH1A1
SCHEMBL5359310 0.70 PTGER4 (0.46) PDE4APDE4BPDE4CPDE4DMAPK8
SCHEMBL5355096 0.68 PDE4A (0.73) PDE4APDE4BPDE4CPDE4DMAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1252157-B1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PROD INC (US) 2004-06-23 EP disclosed
US-6740655-B2 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE 4-SPECIFIC INHIBITORS REDUCE EOSINOPHIL INFLUX TO THE LUNGS; SIDE EFFECT REDUCTION; ANTIINFLAMMATORY AGENT; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS, ESPECIALLY ASTHMA PFIZER INC 2004-05-25 US disclosed
US-20030144300-A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes PFIZER PRODUCTS INC. 2003-07-31 US disclosed
EP-1252157-A1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES Pfizer Products Inc. (US) 2002-10-30 EP disclosed
WO-2001057025-A1 PYRIMIDINE CARBOXAMIDES USEFUL AS INHIBITORS OF PDE4 ISOZYMES PFIZER PRODUCTS INC. (US) 2001-08-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030144300-A1 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes PDE12, PDE4A, PDE4B PDE4A 2/4885PDE4B 3/4885PDE4C 5/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.